These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35638777)

  • 41.
    Karlowsky JA; Hackel MA; Takemura M; Yamano Y; Echols R; Sahm DF
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0199021. PubMed ID: 34807757
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020.
    Karlowsky JA; Lob SH; Chen WT; DeRyke CA; Siddiqui F; Young K; Motyl MR; Sahm DF
    Int J Antimicrob Agents; 2023 Sep; 62(3):106900. PubMed ID: 37354921
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
    Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J
    Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
    [TBL] [Abstract][Full Text] [Related]  

  • 44.
    Chen J; Liu Y; Jia W; Xu X; Sun G; Wang T; Li J; Zhang G; Jing R; Sun H; Xu Y; Liu Y
    Microbiol Spectr; 2023 Jun; 11(3):e0487322. PubMed ID: 37184411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
    Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
    Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Surveillance of Fluoroquinolone Resistance in Wisconsin: Geographic Variation and Impact of Revised CLSI Breakpoints.
    Lazzerini G; Lavey SC; Fox BC; Munson E
    Clin Med Res; 2022 Jun; 20(2):81-88. PubMed ID: 35086853
    [No Abstract]   [Full Text] [Related]  

  • 47. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
    Eagye KJ; Banevicius MA; Nicolau DP
    Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
    Micaëlo M; Brossier F; Bréchot N; Luyt CE; Lu Q; Monsel A; Jarlier V; Aubry A
    Med Mal Infect; 2018 Aug; 48(5):365-371. PubMed ID: 29628176
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers.
    Sader HS; Mendes RE; Kimbrough JH; Kantro V; Castanheira M
    Open Forum Infect Dis; 2023 Feb; 10(2):ofad058. PubMed ID: 36861086
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    Lomovskaya O; Rubio-Aparicio D; Nelson K; Sun D; Tsivkovski R; Castanheira M; Lindley J; Loutit J; Dudley M
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782010
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Investigating of four main carbapenem-resistance mechanisms in high-level carbapenem resistant Pseudomonas aeruginosa isolated from burn patients.
    Rostami S; Farajzadeh Sheikh A; Shoja S; Farahani A; Tabatabaiefar MA; Jolodar A; Sheikhi R
    J Chin Med Assoc; 2018 Feb; 81(2):127-132. PubMed ID: 29033110
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    Karlowsky JA; Hackel MA; Bouchillon SK; Sahm DF
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
    Pillar CM; Torres MK; Brown NP; Shah D; Sahm DF
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4388-99. PubMed ID: 18779357
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimicrobial resistance surveillance of doripenem in China.
    Li Y; Lv Y; Xue F; Zheng B; Liu J; Zhang J
    J Antibiot (Tokyo); 2015 Aug; 68(8):496-500. PubMed ID: 25850342
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
    Lu PL; Liu YC; Toh HS; Lee YL; Liu YM; Ho CM; Huang CC; Liu CE; Ko WC; Wang JH; Tang HJ; Yu KW; Chen YS; Chuang YC; Xu Y; Ni Y; Chen YH; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S37-43. PubMed ID: 22749057
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of
    Wang L; Zhang X; Zhou X; Yang F; Guo Q; Wang M
    Microbiol Spectr; 2023 Jun; 11(3):e0093223. PubMed ID: 37199669
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Contemporary Evaluation of Tebipenem
    Mendes RE; Arends SJR; Streit JM; Critchley I; Cotroneo N; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0205722. PubMed ID: 36625644
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Comparison of antimicrobial use density (AUD) of carbapenem antibacterial agents and investigation of the drug susceptibility of Pseudomonas aeruginosa in 3 hospitals in southern Ibaraki Prefecture, Japan].
    Oishi T; Hitomi S; Kamoshita M; Fukue H; Kawahata D; Fukutake K
    Rinsho Byori; 2008 Jul; 56(7):570-6. PubMed ID: 18709988
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    Yang Y; Guo Y; Yin D; Zheng Y; Wu S; Zhu D; Hu F
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139291
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Geographic Patterns of Carbapenem-Resistant Pseudomonas aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) Program, 2015-2019.
    Lee YL; Ko WC; Hsueh PR
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0200021. PubMed ID: 34807753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.